myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

2021 March for Marrow California - Virtual Walk and 5K

Help us continue to support the patients served by AAMDSIF by registering to run in our 2021 Virtual Walk and 5K or simply by donating. We look forward to walking and running with you the week of April 24 - May 1, 2021, and continuing the celebration of the brave patients and families that are fighting

Event Date: 
Sat, 04/24/2021 to Sat, 05/01/2021
Community Event Type: 

2021 March for Marrow Texas - VIRTUAL Walk and 5K

Join together virtually with fellow patients, families, caregivers, and friends to raise awareness for

Event Date: 
Sat, 03/27/2021 to Sat, 04/03/2021
Community Event Type: 

Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy

Author(s): 
Lee S, Desai P, Edirisinghe B, Pianello S, Curcio T, Samuel M, Ritchie EK, Roboz GJ
Primary Author: 
Lee S
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Oct 2020
Bone Marrow Diseases: 

Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?

Author(s): 
Bewersdorf JP, Zeidan AM
Primary Author: 
Bewersdorf JP
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Oct 2020

For most patients with higher-risk

Bone Marrow Diseases: 

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

Author(s): 
Steensma DP, Fenaux P, Van Eygen K, Raza A, Santini V, Germing U, Font P, Diez-Campelo M, Thepot S, Vellenga E, Patnaik MM, Jang JH, Varsos H, Bussolari J, Rose E, Sherman L, Sun L, Wan Y, Dougherty S, Huang F, Feller F, Rizo A, Platzbecker U
Primary Author: 
Steensma DP
Journal Title: 
Journal of clinical oncology: official journal of the American Society Clinical Oncology
Original Publication Date: 
Oct 2020

Purpose: Patients with lower-risk (LR)

Bone Marrow Diseases: 

David Jacobsohn, MD, ScM

Jacobsohn, David
Division Chief, Blood and Marrow Transplanation
Children's National

David Jacobsohn, MD, ScM is the Division Chief, Blood and Marrow Transplanation at Children's National Hospital in Washington, D.C.   Previously, he was at Children’s Memorial Hospital in Chicago, where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. Dr.